110 related articles for article (PubMed ID: 35786664)
1. β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer.
Eurola A; Ristimäki A; Mustonen H; Nurmi AM; Hagström J; Kallio P; Alitalo K; Haglund C; Seppänen H
Tumour Biol; 2022; 44(1):69-84. PubMed ID: 35786664
[TBL] [Abstract][Full Text] [Related]
2. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
3. Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.
Eurola A; Ristimäki A; Mustonen H; Nurmi AM; Hagström J; Haglund C; Seppänen H
Sci Rep; 2021 May; 11(1):9896. PubMed ID: 33972616
[TBL] [Abstract][Full Text] [Related]
4. Positive regulation of β-catenin-PROX1 signaling axis by DBC1 in colon cancer progression.
Yu EJ; Kim SH; Kim HJ; Heo K; Ou CY; Stallcup MR; Kim JH
Oncogene; 2016 Jun; 35(26):3410-8. PubMed ID: 26477307
[TBL] [Abstract][Full Text] [Related]
5. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
6. Complementary Wnt Sources Regulate Lymphatic Vascular Development via PROX1-Dependent Wnt/β-Catenin Signaling.
Cha B; Geng X; Mahamud MR; Zhang JY; Chen L; Kim W; Jho EH; Kim Y; Choi D; Dixon JB; Chen H; Hong YK; Olson L; Kim TH; Merrill BJ; Davis MJ; Srinivasan RS
Cell Rep; 2018 Oct; 25(3):571-584.e5. PubMed ID: 30332639
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
[TBL] [Abstract][Full Text] [Related]
8. Hyperglycemia Promotes Pancreatic Cancer Initiation and Progression by Activating the Wnt/β-Catenin Signaling Pathway.
Chen H; Zhao J; Jiang N; Wang Z; Liu C
Anticancer Agents Med Chem; 2021; 21(18):2592-2602. PubMed ID: 33563184
[TBL] [Abstract][Full Text] [Related]
9. Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61.
Sano M; Driscoll DR; DeJesus-Monge WE; Quattrochi B; Appleman VA; Ou J; Zhu LJ; Yoshida N; Yamazaki S; Takayama T; Sugitani M; Nemoto N; Klimstra DS; Lewis BC
Neoplasia; 2016 Dec; 18(12):785-794. PubMed ID: 27889647
[TBL] [Abstract][Full Text] [Related]
10. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
11. PROX1 promotes breast cancer invasion and metastasis through WNT/β-catenin pathway via interacting with hnRNPK.
Zhu L; Tian Q; Gao H; Wu K; Wang B; Ge G; Jiang S; Wang K; Zhou C; He J; Liu P; Ren Y; Wang B
Int J Biol Sci; 2022; 18(5):2032-2046. PubMed ID: 35342346
[No Abstract] [Full Text] [Related]
12. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
13. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
[TBL] [Abstract][Full Text] [Related]
15. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
17. The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy.
Nurmi AM; Hagström J; Mustonen H; Seppänen H; Haglund C
PLoS One; 2022; 17(5):e0267792. PubMed ID: 35536778
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer.
Fisher AV; Abbott DE; Venkatesh M; Leverson GE; Campbell-Flohr SA; Ronnekleiv-Kelly SM; Greenberg CC; Winslow ER; Weber SM
Ann Surg Oncol; 2018 Sep; 25(9):2661-2668. PubMed ID: 30003452
[TBL] [Abstract][Full Text] [Related]
20. Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy.
Kudo M; Ishii G; Gotohda N; Konishi M; Takahashi S; Kobayashi S; Sugimoto M; Martin JD; Cabral H; Kojima M
Oncol Rep; 2022 Jul; 48(1):. PubMed ID: 35583018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
